Literature DB >> 7637014

RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA.

H Grosfeld1, M G Hill, P L Collins.   

Abstract

Previously, a cDNA was constructed so that transcription by T7 RNA polymerase yielded a approximately 1-kb negative-sense analog of genomic RNA of human respiratory syncytial virus (RSV) containing the gene for chloramphenicol acetyltransferase (CAT) under the control of putative RSV transcription motifs and flanked by the RSV genomic termini. When transfected into RSV-infected cells, this minigenome was "rescued," as evidenced by high levels of CAT expression and the production of transmissible particles which propagated and expressed high levels of CAT expression during serial passage (P.L. Collins, M. A. Mink, and D. S. Stec, Proc. Natl. Acad. Sci. USA, 88:9663-9667, 1991). Here, this cDNA, together with a second one designed to yield an exact-copy positive-sense RSV-CAT RNA antigenome, were each modified to contain a self-cleaving hammerhead ribozyme for the generation of a nearly exact 3' end. Each cDNA was transfected into cells infected with a vaccinia virus recombinant expressing T7 RNA polymerase, together with plasmids encoding the RSV N, P, and L proteins, each under the control of a T7 promoter. When the plasmid-supplied template was the mini-antigenome, the minigenome was produced. When the plasmid-supplied template was the minigenome, the products were mini-antigenome, subgenomic polyadenylated mRNA and progeny minigenome. Identification of progeny minigenome made from the plasmid-supplied minigenome template indicates that the full RSV RNA replication cycle occurred. RNA synthesis required all three RSV proteins, N, P, and L, and was ablated completely by the substitution of Asn for Asp at position 989 in the L protein. Thus, the N, P, and L proteins were sufficient for the synthesis of correct minigenome and antigenome, but this was not the case for subgenomic mRNA, indicating that the requirements for RNA replication and transcription are not identical. Complementation with N, P, and L alone yielded an mRNA pattern containing a large fraction of molecules of incomplete, heterogeneous size. In contrast, complementation with RSV (supplying all of the RSV gene products) yielded a single discrete mRNA band. Superinfection with RSV of cells staging N/P/L-based RNA synthesis yielded the single discrete mRNA species. Some additional factor supplied by RSV superinfection appeared to be involved in transcription, the most obvious possibility being one or more additional RSV gene products.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7637014      PMCID: PMC189426     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

Review 1.  Genetic manipulation of negative-strand RNA virus genomes.

Authors:  A García-Sastre; P Palese
Journal:  Annu Rev Microbiol       Date:  1993       Impact factor: 15.500

2.  Rescue of synthetic analogs of genomic RNA and replicative-intermediate RNA of human parainfluenza virus type 3.

Authors:  K Dimock; P L Collins
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

3.  The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA.

Authors:  P Calain; L Roux
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

4.  Rescue of a 7502-nucleotide (49.3% of full-length) synthetic analog of respiratory syncytial virus genomic RNA.

Authors:  P L Collins; M A Mink; M G Hill; E Camargo; H Grosfeld; D S Stec
Journal:  Virology       Date:  1993-07       Impact factor: 3.616

5.  Extent of terminal complementarity modulates the balance between transcription and replication of vesicular stomatitis virus RNA.

Authors:  G W Wertz; S Whelan; A LeGrone; L A Ball
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-30       Impact factor: 11.205

6.  RNA editing in Newcastle disease virus.

Authors:  M Steward; I B Vipond; N S Millar; P T Emmerson
Journal:  J Gen Virol       Date:  1993-12       Impact factor: 3.891

7.  Rescue of synthetic analogs of genome RNA of human parainfluenza virus type 3.

Authors:  B P De; A K Banerjee
Journal:  Virology       Date:  1993-09       Impact factor: 3.616

8.  Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis.

Authors:  J E Crowe; P T Bui; W T London; A R Davis; P P Hung; R M Chanock; B R Murphy
Journal:  Vaccine       Date:  1994-06       Impact factor: 3.641

9.  Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins.

Authors:  K K Conzelmann; M Schnell
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

10.  Infectious defective interfering particles of VSV from transcripts of a cDNA clone.

Authors:  A K Pattnaik; L A Ball; A W LeGrone; G W Wertz
Journal:  Cell       Date:  1992-06-12       Impact factor: 41.582

View more
  102 in total

1.  The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription.

Authors:  A Bermingham; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Expression of the ORF-2 protein of the human respiratory syncytial virus M2 gene is initiated by a ribosomal termination-dependent reinitiation mechanism.

Authors:  G Ahmadian; J S Randhawa; A J Easton
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

3.  A single amino acid substitution in the phosphoprotein of respiratory syncytial virus confers thermosensitivity in a reconstituted RNA polymerase system.

Authors:  A C Marriott; S D Wilson; J S Randhawa; A J Easton
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  Domains of human respiratory syncytial virus P protein essential for homodimerization and for binding to N and NS1 protein.

Authors:  U Hengst; P Kiefer
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

5.  Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assembly.

Authors:  Anuradha Radhakrishnan; Dawn Yeo; Gaie Brown; Myint Zu Myaing; Laxmi Ravi Iyer; Roland Fleck; Boon-Huan Tan; Jim Aitken; Duangmanee Sanmun; Kai Tang; Andy Yarwood; Jacob Brink; Richard J Sugrue
Journal:  Mol Cell Proteomics       Date:  2010-06-08       Impact factor: 5.911

6.  Characterization of a viral phosphoprotein binding site on the surface of the respiratory syncytial nucleoprotein.

Authors:  Marie Galloux; Bogdan Tarus; Ilfad Blazevic; Jenna Fix; Stéphane Duquerroy; Jean-François Eléouët
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

7.  Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents.

Authors:  H Jin; X Cheng; H Z Zhou; S Li; A Seddiqui
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.

Authors:  Joshua M DiNapoli; Lijuan Yang; Amorsolo Suguitan; Subbiah Elankumaran; David W Dorward; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  Interaction between human respiratory syncytial virus (RSV) M2-1 and P proteins is required for reconstitution of M2-1-dependent RSV minigenome activity.

Authors:  Stephen W Mason; Erika Aberg; Carol Lawetz; Rachel DeLong; Paul Whitehead; Michel Liuzzi
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 10.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.